Precision BioSciences Reports Q4 Revenue of $34.2M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Should l Buy DTIL?
Reports Q4 revenue $34.2M, consensus $9.07M. The increase of $33.6M in revenue during the quarter ended December 31, 2025 was primarily the result of recognizing $26.2M in revenue under the Novartis agreement following conclusion of the hemoglobinopathy collaboration in October 2025 and recognition of $8M in revenue under the Imugene license agreement. "2025 was an exceptional year for Precision BioSciences marked by meaningful clinical and financial progress. We delivered on what we committed to achieve and more in 2025 positioning Precision BioSciences for success in 2026 and beyond," said Michael Amoroso, Chief Executive Officer. "The evidence supporting the clinical utility of ARCUS for in vivo gene editing continues to mount in diseases with high unmet need led by advancement of PBGENE-HBV through multiple cohorts in our ELIMINATE-B study for chronic hepatitis B. At The Liver Meeting(R) 2025, we presented late-breaking clinical data showing safety and cumulative, dose-dependent antiviral activity along with paired biopsy findings that provide the first molecular evidence consistent with viral DNA gene editing in patients. In another first, our partner iECURE achieved a complete response in the first infant with neonatal onset OTC deficiency following treatment with ECUR-506 which utilizes an ARCUS nuclease developed by Precision for in vivo gene insertion."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DTIL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DTIL
Wall Street analysts forecast DTIL stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.420
Low
30.00
Averages
45.00
High
60.00
Current: 5.420
Low
30.00
Averages
45.00
High
60.00
No data
About DTIL
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
iECURE's ECUR-506 Selected for FDA CMC Program
- FDA Program Participation: iECURE's ECUR-506 has been selected by the FDA to participate in the Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot Program, which is expected to enhance engagement with the FDA, thereby accelerating clinical development and strengthening the company's competitive position in the neonatal OTC deficiency treatment market.
- Clinical Trial Progress: ECUR-506 is currently being evaluated in the OTC-HOPE clinical trial for male infants with neonatal-onset OTC deficiency, having received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations, with promising clinical responses observed, and additional data expected to be released in the first half of 2026.
- Manufacturing Capability Enhancement: Participation in the FDA's CMC program will enable iECURE to improve its manufacturing capabilities while advancing ECUR-506, ensuring that production readiness aligns with clinical progress ahead of a potential Biologics License Application (BLA) submission to meet market demand.
- Strategic Importance: iECURE's CEO Joe Truitt emphasized that the selection for this program underscores the critical importance of aligning clinical progress with manufacturing readiness in developing complex genetic medicines, aiming to bring ECUR-506 to market swiftly to benefit newborn patients.
See More
Precision BioSciences Q4 Earnings Exceed Expectations
- Strong Performance: Precision BioSciences reported a Q4 GAAP EPS of $1.05, beating expectations by $1.59, which highlights a significant improvement in profitability and boosts investor confidence.
- Revenue Surge: The company achieved revenues of $34 million, exceeding market expectations by $24.93 million, indicating robust demand for its products and services, potentially driving future business expansion.
- Positive Stock Reaction: Following the earnings release, Precision BioSciences' shares rose by 8%, reflecting the market's favorable response to its financial performance, which may attract more investor interest.
- Future Outlook: The company anticipates providing potential proof-of-concept data for an HBV cure in 2026, which could drive long-term growth and further solidify its position in the biopharmaceutical sector.
See More
Precision BioSciences Unveils PBGENE-HBV Clinical Data at AASLD
- Clinical Trial Progress: The Phase 1 data for PBGENE-HBV presented at AASLD indicates that 13 patients have been treated across the first five cohorts, demonstrating good safety and tolerability, with dose-dependent antiviral activity, marking a significant advancement in chronic hepatitis B treatment.
- Successful Fundraising: The company raised $75 million in November 2025, extending its cash runway through 2028 to support multiple clinical inflection points for PBGENE-HBV and PBGENE-DMD, enhancing financial stability.
- IND Approval and New Trial Launch: PBGENE-DMD received IND clearance from the FDA in 2026, allowing the initiation of the Phase 1/2 FUNCTION-DMD clinical trial, with initial data from multiple patients expected by year-end 2026, further advancing treatment for Duchenne muscular dystrophy.
- Enhanced Patent Protection: In March 2026, the company received two Notices of Allowance related to PBGENE-HBV, extending patent expiration to 2044, ensuring competitive advantage in hepatitis B treatment.
See More
Precision BioSciences to Announce Q4 Earnings on March 12
- Earnings Announcement: Precision BioSciences is set to release its Q4 earnings report on March 12 before market open, with investors keenly awaiting the results to gauge the company's future growth potential.
- Earnings Expectations: The consensus EPS estimate stands at -$0.64, reflecting a 71.2% year-over-year improvement, indicating the company's efforts to enhance profitability, although it remains in a loss position.
- Revenue Growth Forecast: Revenue is projected at $9.07 million, representing a staggering 1317.2% year-over-year increase, showcasing significant progress in market demand and product promotion, potentially laying the groundwork for future growth.
- Historical Performance Review: Over the past year, Precision BioSciences has beaten EPS and revenue estimates 50% of the time, suggesting a degree of stability and market confidence in the company's financial performance.
See More
Precision BioSciences Secures Two Patent Allowances
- Patent Progress: Precision BioSciences has received two Notices of Allowance from the USPTO for its PBGENE-HBV program, which is expected to provide significant composition-of-matter protection for the ARCUS nuclease until 2044, thereby enhancing its competitive position in the Hepatitis B treatment market.
- Innovation Protection: The first patent application pertains to engineered meganucleases targeting the Hepatitis B virus genome, while the second covers polypeptide linkers for engineered meganucleases, ensuring intellectual property protection for future ARCUS nucleases and further solidifying the company's technological barriers.
- Clinical Trial Outlook: PBGENE-HBV is the first-in-human clinical trial targeting chronic Hepatitis B infection, aiming to eliminate cccDNA and potentially provide a curative treatment, with the FDA granting it Fast Track designation, indicating strong market anticipation for this therapy.
- Intellectual Property Strategy: The acquisition of these patents not only strengthens Precision's intellectual property portfolio but also provides overlapping patent coverage for the PBGENE-HBV program, ensuring the company has robust legal protection and market advantages in future R&D and commercialization efforts.
See More
Precision BioSciences Secures Two Patent Allowances
- Patent Progress: Precision BioSciences has received two Notices of Allowance from the USPTO for its PBGENE-HBV program, which is expected to provide significant protection for the ARCUS nuclease until 2044, thereby enhancing its competitive position in the Hepatitis B treatment market.
- Innovation Protection: The first patent application pertains to engineered meganucleases targeting the Hepatitis B virus genome, while the second covers polypeptide linkers for engineered meganucleases, ensuring broader intellectual property protection for future ARCUS nucleases and maintaining the uniqueness of its technology.
- Clinical Trial Outlook: PBGENE-HBV is the world's first clinical trial program targeting chronic Hepatitis B infection, aiming for potential cure by eliminating cccDNA, which is expected to significantly improve patient outcomes and drive the company's growth in the biopharmaceutical sector.
- FDA Fast Track Designation: The program has received Fast Track designation from the FDA, indicating its potential to meet high unmet medical needs, further boosting investor confidence in Precision BioSciences' future development.
See More
iECURE's ECUR-506 Selected for FDA CMC Program
- FDA Program Participation: iECURE's ECUR-506 has been selected by the FDA to participate in the Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot Program, which is expected to enhance engagement with the FDA, thereby accelerating clinical development and strengthening the company's competitive position in the neonatal OTC deficiency treatment market.
- Clinical Trial Progress: ECUR-506 is currently being evaluated in the OTC-HOPE clinical trial for male infants with neonatal-onset OTC deficiency, having received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations, with promising clinical responses observed, and additional data expected to be released in the first half of 2026.
- Manufacturing Capability Enhancement: Participation in the FDA's CMC program will enable iECURE to improve its manufacturing capabilities while advancing ECUR-506, ensuring that production readiness aligns with clinical progress ahead of a potential Biologics License Application (BLA) submission to meet market demand.
- Strategic Importance: iECURE's CEO Joe Truitt emphasized that the selection for this program underscores the critical importance of aligning clinical progress with manufacturing readiness in developing complex genetic medicines, aiming to bring ECUR-506 to market swiftly to benefit newborn patients.
See More
Precision BioSciences Q4 Earnings Exceed Expectations
- Strong Performance: Precision BioSciences reported a Q4 GAAP EPS of $1.05, beating expectations by $1.59, which highlights a significant improvement in profitability and boosts investor confidence.
- Revenue Surge: The company achieved revenues of $34 million, exceeding market expectations by $24.93 million, indicating robust demand for its products and services, potentially driving future business expansion.
- Positive Stock Reaction: Following the earnings release, Precision BioSciences' shares rose by 8%, reflecting the market's favorable response to its financial performance, which may attract more investor interest.
- Future Outlook: The company anticipates providing potential proof-of-concept data for an HBV cure in 2026, which could drive long-term growth and further solidify its position in the biopharmaceutical sector.
See More
Precision BioSciences Unveils PBGENE-HBV Clinical Data at AASLD
- Clinical Trial Progress: The Phase 1 data for PBGENE-HBV presented at AASLD indicates that 13 patients have been treated across the first five cohorts, demonstrating good safety and tolerability, with dose-dependent antiviral activity, marking a significant advancement in chronic hepatitis B treatment.
- Successful Fundraising: The company raised $75 million in November 2025, extending its cash runway through 2028 to support multiple clinical inflection points for PBGENE-HBV and PBGENE-DMD, enhancing financial stability.
- IND Approval and New Trial Launch: PBGENE-DMD received IND clearance from the FDA in 2026, allowing the initiation of the Phase 1/2 FUNCTION-DMD clinical trial, with initial data from multiple patients expected by year-end 2026, further advancing treatment for Duchenne muscular dystrophy.
- Enhanced Patent Protection: In March 2026, the company received two Notices of Allowance related to PBGENE-HBV, extending patent expiration to 2044, ensuring competitive advantage in hepatitis B treatment.
See More
Precision BioSciences to Announce Q4 Earnings on March 12
- Earnings Announcement: Precision BioSciences is set to release its Q4 earnings report on March 12 before market open, with investors keenly awaiting the results to gauge the company's future growth potential.
- Earnings Expectations: The consensus EPS estimate stands at -$0.64, reflecting a 71.2% year-over-year improvement, indicating the company's efforts to enhance profitability, although it remains in a loss position.
- Revenue Growth Forecast: Revenue is projected at $9.07 million, representing a staggering 1317.2% year-over-year increase, showcasing significant progress in market demand and product promotion, potentially laying the groundwork for future growth.
- Historical Performance Review: Over the past year, Precision BioSciences has beaten EPS and revenue estimates 50% of the time, suggesting a degree of stability and market confidence in the company's financial performance.
See More
Precision BioSciences Secures Two Patent Allowances
- Patent Progress: Precision BioSciences has received two Notices of Allowance from the USPTO for its PBGENE-HBV program, which is expected to provide significant composition-of-matter protection for the ARCUS nuclease until 2044, thereby enhancing its competitive position in the Hepatitis B treatment market.
- Innovation Protection: The first patent application pertains to engineered meganucleases targeting the Hepatitis B virus genome, while the second covers polypeptide linkers for engineered meganucleases, ensuring intellectual property protection for future ARCUS nucleases and further solidifying the company's technological barriers.
- Clinical Trial Outlook: PBGENE-HBV is the first-in-human clinical trial targeting chronic Hepatitis B infection, aiming to eliminate cccDNA and potentially provide a curative treatment, with the FDA granting it Fast Track designation, indicating strong market anticipation for this therapy.
- Intellectual Property Strategy: The acquisition of these patents not only strengthens Precision's intellectual property portfolio but also provides overlapping patent coverage for the PBGENE-HBV program, ensuring the company has robust legal protection and market advantages in future R&D and commercialization efforts.
See More
Precision BioSciences Secures Two Patent Allowances
- Patent Progress: Precision BioSciences has received two Notices of Allowance from the USPTO for its PBGENE-HBV program, which is expected to provide significant protection for the ARCUS nuclease until 2044, thereby enhancing its competitive position in the Hepatitis B treatment market.
- Innovation Protection: The first patent application pertains to engineered meganucleases targeting the Hepatitis B virus genome, while the second covers polypeptide linkers for engineered meganucleases, ensuring broader intellectual property protection for future ARCUS nucleases and maintaining the uniqueness of its technology.
- Clinical Trial Outlook: PBGENE-HBV is the world's first clinical trial program targeting chronic Hepatitis B infection, aiming for potential cure by eliminating cccDNA, which is expected to significantly improve patient outcomes and drive the company's growth in the biopharmaceutical sector.
- FDA Fast Track Designation: The program has received Fast Track designation from the FDA, indicating its potential to meet high unmet medical needs, further boosting investor confidence in Precision BioSciences' future development.
See More
